Genentech (in collaboration with Roche Pharma AG)
- Ocrelizumab is administered via intravenous infusion.
- Like Rituxan, this drug is an anti-CD20 monoclonal antibody. It has the potential advantage of being more like human antibody than Rituxan.
- A Phase II study, with 250 participants, is ongoing. It will compare the treatment with Ocrelizumab versus Avonex and placebo; all treatment arms include the repeated IV administration of methylprednisolone. The primary outcome measure is the total number of gadolinium-enhancing T1 lesions as observed on MRI scans of the brain. Secondary outcome measures include the annualized relapse rate, the proportion of patients who remain relapse-free, and the change in total volume of T2 lesions on MRI scans of the brain.
- The study began in April 2008 and is estimated to be completed in January 2012.